Neil Carragher
Prof
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Professor Neil Carragher is a faculty member at the University of Edinburgh, UK. His research focuses on cancer therapy, particularly the development of pro-regenerative therapies and kinase inhibitors, as evidenced by his recent articles on targeting the Wnt pathway and glioblastoma heterogeneity. He also explores cellular mechanisms involved in tumor progression and innovative high content imaging techniques.
Positions (1)
Pei San (Sharel) E
University of Edinburgh
9 months ago
The University of Edinburgh, in collaboration with the University of Glasgow, is offering a fully funded PhD position in Precision Medicine focused on the development of pH-sensitive Metal–Organic Frameworks (MOFs) for targeted drug delivery in pancreatic cancer. This interdisciplinary project is supervised by Dr Pei San (Sharel) E, Prof Neil Carragher, Prof Jennifer Morton, and Prof David Chang, bringing together expertise in chemical engineering, cancer biology, and drug discovery. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a five-year survival rate below 5%. Current treatments are limited by non-specific toxicity and severe side effects. The project aims to address these challenges by developing smart nanocarriers—specifically, MOFs—that can encapsulate both KRASG12D inhibitors and chemotherapeutic agents, releasing them in response to the acidic tumor microenvironment. This targeted approach is expected to improve therapeutic efficacy and reduce side effects. Students will gain hands-on experience in advanced materials synthesis and characterization, including MOF synthesis, drug encapsulation, and pH-sensitive release studies. The project also involves preclinical work with pancreatic cancer cell lines and genetically engineered mouse models, providing comprehensive training in both in vitro and in vivo research. Collaboration across materials chemistry, cancer biology, and clinical oncology will foster interdisciplinary skills and team-based problem-solving. Applicants should have a strong background in materials science, chemistry, biomedical engineering, or a related field. Experience with drug delivery, cancer biology, or preclinical models is advantageous. The position is fully funded, covering tuition and a stipend, as part of the Precision Medicine Doctoral Training Programme. The application deadline is 12 January 2026, with a start date in September 2026. To apply, candidates must submit an application via the EUCLID system, including the Precision Medicine Recruitment Form and a CV. Q&A sessions with the supervisors will be held in early December for prospective applicants. For more information and application details, visit the provided links.
9 months ago
Articles (15)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Collaborators (13)
Ruslan Dmitriev
Assistant Professor
Ghent University
Stephen Robbins
Professor
McGill University
Cláudio Alexandre Almeida Pinheiro
Ghent University
Gregory Way
Assistant Professor
University of Colorado Anschutz Medical Campus
Asier Unciti-Broceta
Professor of Medicinal Chemistry
University of Edinburgh
Prakash Ramachandran
Professor of Experimental Hepatology
University of Edinburgh
David Pearce
University College London
Catherine Adam
Cancer Research UK
Steven Shave
University of Edinburgh
Adam Byron
Lecturer
The University of Manchester
Aaron R. Wheeler
University of Toronto
Helena Chaytow
-
Catherina Becker
Professor of Neural Development and Regeneration
Technische Universität Dresden
Make your next move.
Prepare your application
Review drafts before you send them.